Do analysts prefer NERV or INCR?

Minerva Neurosciences currently has a consensus target price of $10.33, indicating a potential upside of 113.50%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Minerva Neurosciences is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NERV or INCR more profitable?

Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% InterCure N/A N/A N/A

Does the media prefer NERV or INCR?

In the previous week, InterCure had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for InterCure and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.93 beat InterCure's score of 0.23 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InterCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend INCR or CRDL?

Cardiol Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 415.46%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is INCR or CRDL more profitable?

InterCure's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Cardiol Therapeutics N/A -180.44% -140.28%

Does the media favor INCR or CRDL?

In the previous week, InterCure had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for InterCure and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.96 beat InterCure's score of 0.23 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InterCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INCR or SLGL?

Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 187.02%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Do analysts recommend IMUX or INCR?

Immunic presently has a consensus target price of $47.25, indicating a potential upside of 206.82%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, IMUX or INCR?

InterCure has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A InterCure $78.47M 0.81 -$10.37M $0.03 192.67

Is IMUX or INCR more profitable?

InterCure's return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% InterCure N/A N/A N/A

Does the media prefer IMUX or INCR?

In the previous week, InterCure had 2 more articles in the media than Immunic. MarketBeat recorded 6 mentions for InterCure and 4 mentions for Immunic. Immunic's average media sentiment score of 0.47 beat InterCure's score of 0.23 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InterCure 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend INCR or SIGA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

InterCure (INCR) Competitors

$5.78 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$5.78 +0.00 (+0.09%)

As of 03:59 AM Eastern

Compare

INCR vs. NERV, CRDL, SLGL, IMUX, and SIGA

Should you buy InterCure stock or one of its competitors? InterCure's main competitors and comparable companies include Minerva Neurosciences (NERV), Cardiol Therapeutics (CRDL), Sol-Gel Technologies (SLGL), Immunic (IMUX), and Siga Technologies (SIGA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does InterCure compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market. Comparatively, InterCure has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Minerva Neurosciences currently has a consensus target price of $10.33, indicating a potential upside of 113.50%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Minerva Neurosciences is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

InterCure has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
InterCure	$78.47M	0.81	-$10.37M	$0.03	192.67

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
InterCure	N/A	N/A	N/A

In the previous week, InterCure had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for InterCure and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.93 beat InterCure's score of 0.23 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

InterCure beats Minerva Neurosciences on 7 of the 13 factors compared between the two stocks.

How does InterCure compare to Cardiol Therapeutics?

InterCure (NASDAQ:INCR) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

8.3% of InterCure shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Cardiol Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 415.46%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, InterCure had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for InterCure and 3 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.96 beat InterCure's score of 0.23 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cardiol Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InterCure has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

InterCure has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.81	-$10.37M	$0.03	192.67
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Summary

InterCure beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does InterCure compare to Sol-Gel Technologies?

InterCure (NASDAQ:INCR) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 187.02%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

8.3% of InterCure shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sol-Gel Technologies has lower revenue, but higher earnings than InterCure. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.81	-$10.37M	$0.03	192.67
Sol-Gel Technologies	$19.39M	9.97	-$6.13M	-$5.64	N/A

InterCure has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. InterCure's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

In the previous week, InterCure had 5 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 6 mentions for InterCure and 1 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 1.87 beat InterCure's score of 0.23 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Sol-Gel Technologies	Very Positive

InterCure has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Summary

Sol-Gel Technologies beats InterCure on 9 of the 17 factors compared between the two stocks.

How does InterCure compare to Immunic?

Immunic (NASDAQ:IMUX) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
InterCure	N/A	N/A	N/A

Immunic has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, InterCure has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

In the previous week, InterCure had 2 more articles in the media than Immunic. MarketBeat recorded 6 mentions for InterCure and 4 mentions for Immunic. Immunic's average media sentiment score of 0.47 beat InterCure's score of 0.23 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

InterCure has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
InterCure	$78.47M	0.81	-$10.37M	$0.03	192.67

Immunic presently has a consensus target price of $47.25, indicating a potential upside of 206.82%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Immunic beats InterCure on 8 of the 15 factors compared between the two stocks.

How does InterCure compare to Siga Technologies?

InterCure (NASDAQ:INCR) and Siga Technologies (NASDAQ:SIGA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

InterCure has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Siga Technologies has higher revenue and earnings than InterCure. Siga Technologies is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.81	-$10.37M	$0.03	192.67
Siga Technologies	$94.57M	2.32	$23.28M	-$0.05	N/A

InterCure has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. InterCure's return on equity of 0.00% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Siga Technologies	-5.19%	-1.55%	-1.32%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, InterCure had 5 more articles in the media than Siga Technologies. MarketBeat recorded 6 mentions for InterCure and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.89 beat InterCure's score of 0.23 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Siga Technologies	Very Positive

8.3% of InterCure shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

InterCure beats Siga Technologies on 7 of the 13 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCR vs. The Competition

Export

Metric	InterCure	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63.23M	$12.11B	$7.18B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.27%
P/E Ratio	192.67	787.65	273.17	25.45
Price / Sales	0.81	759.94	638.21	103.75
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.55	10.49	11.08	6.36
Net Income	-$10.37M	$2.83B	$3.48B	$349.79M
7 Day Performance	5.47%	0.58%	0.38%	-0.40%
1 Month Performance	20.19%	5.69%	7.89%	4.24%
1 Year Performance	-27.75%	6.19%	24.71%	15.13%

InterCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCR InterCure	0.633 of 5 stars	$5.78 flat	N/A	-27.8%	$63.23M	$78.47M	192.67	350
NERV Minerva Neurosciences	2.3743 of 5 stars	$5.43 +8.6%	$10.33 +90.3%	+105.1%	$238.74M	N/A	N/A	9
CRDL Cardiol Therapeutics	2.6687 of 5 stars	$2.14 +7.0%	$10.00 +367.3%	+79.6%	$231.77M	N/A	N/A	20	Positive News High Trading Volume
SLGL Sol-Gel Technologies	3.8567 of 5 stars	$79.43 -2.8%	$197.50 +148.6%	+201.9%	$229.62M	$19.39M	N/A	50	Positive News Gap Up
IMUX Immunic	3.126 of 5 stars	$16.49 +0.4%	$47.25 +186.5%	+87.8%	$224.99M	N/A	N/A	70	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCR) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InterCure (INCR) Competitors

INCR vs. NERV, CRDL, SLGL, IMUX, and SIGA

How does InterCure compare to Minerva Neurosciences?

Summary

How does InterCure compare to Cardiol Therapeutics?

Summary

How does InterCure compare to Sol-Gel Technologies?

Summary

How does InterCure compare to Immunic?

Summary

How does InterCure compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InterCure (INCR) Competitors

INCR vs. NERV, CRDL, SLGL, IMUX, and SIGA

How does InterCure compare to Minerva Neurosciences?

Which has more volatility & risk, NERV or INCR?

Do analysts prefer NERV or INCR?

Do institutionals & insiders believe in NERV or INCR?

Which has higher valuation & earnings, NERV or INCR?

Is NERV or INCR more profitable?

Does the media prefer NERV or INCR?

Summary

How does InterCure compare to Cardiol Therapeutics?

Do institutionals and insiders hold more shares of INCR or CRDL?

Is INCR or CRDL more profitable?

Do analysts recommend INCR or CRDL?

Does the media favor INCR or CRDL?

Which has more volatility & risk, INCR or CRDL?

Which has better valuation and earnings, INCR or CRDL?

Summary

How does InterCure compare to Sol-Gel Technologies?

Do analysts rate INCR or SLGL?

Do insiders and institutionals have more ownership in INCR or SLGL?

Which has preferable valuation & earnings, INCR or SLGL?

Is INCR or SLGL more profitable?

Does the media prefer INCR or SLGL?

Which has more risk and volatility, INCR or SLGL?

Summary

How does InterCure compare to Immunic?

Do institutionals & insiders believe in IMUX or INCR?

Is IMUX or INCR more profitable?

Which has more risk and volatility, IMUX or INCR?

Does the media prefer IMUX or INCR?

Which has preferable earnings & valuation, IMUX or INCR?

Do analysts recommend IMUX or INCR?

Summary

How does InterCure compare to Siga Technologies?

Which has more risk & volatility, INCR or SIGA?

Which has better earnings & valuation, INCR or SIGA?

Is INCR or SIGA more profitable?

Do analysts recommend INCR or SIGA?

Does the media prefer INCR or SIGA?

Do insiders and institutionals hold more shares of INCR or SIGA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools